{"id":242459,"date":"2026-02-23T01:16:45","date_gmt":"2026-02-23T01:16:45","guid":{"rendered":"https:\/\/evertise.net\/?p=131306"},"modified":"2026-02-23T01:16:45","modified_gmt":"2026-02-23T01:16:45","slug":"building-agi-for-pharmaceutical-industry-deep-intelligent-pharma-secures-another-us60-million-in-funding","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2026\/02\/23\/building-agi-for-pharmaceutical-industry-deep-intelligent-pharma-secures-another-us60-million-in-funding\/","title":{"rendered":"Building AGI for Pharmaceutical Industry, Deep Intelligent Pharma Secures Another US$60 Million in Funding"},"content":{"rendered":"

AI pharmaceutical-development unicorn <\/span>Deep Intelligent Pharma<\/b><\/a> has recently completed a new financing round of <\/span>US$60 million<\/b>. New investors in this round include <\/span>Trustar Capital<\/b>, <\/span>Jinyi Capital<\/b>, and <\/span>Kaitai Capital<\/b>, while existing shareholders <\/span>CDH Investments<\/b> and <\/span>Xinding Capital<\/b> continued to increase their stakes. <\/span>Index Capital<\/b> served as the exclusive financial advisor for the transaction. The newly raised funds will be primarily used to upgrade the company\u2019s core technology systems.<\/span><\/p>\n

Notably, in <\/span>December last year<\/b>, Deep Intelligent Pharma had just announced a <\/span>US$50 million Series D<\/b> financing. In less than two months, the company has raised <\/span>over US$100 million<\/b> in total.<\/span><\/p>\n

At present, due to technical limitations, most companies still apply AI mainly to the <\/span>pre-clinical stage<\/b> of pharmaceutical development. In contrast, Deep Intelligent Pharma provides global pharmaceutical companies with <\/span>end-to-end intelligent solutions<\/b>, covering <\/span>pre-clinical research, regulatory submission, clinical trials, and post-marketing studies<\/b>.<\/span><\/p>\n

According to the company, in past projects, <\/span>clinical trial protocols generated by <\/b>Deep Intelligent Pharma\u2019s<\/span> AI \u201cbrain\u201d achieved \u201czero revisions\u201d and passed regulatory review in a single submission<\/b>, highlighting its practical regulatory-grade capability.<\/span><\/p>\n

From Single-Function Tools to an AI \u201cDigital Scientist Team\u201d<\/b><\/p>\n

Historically, the pharmaceutical market has been more willing to pay for pharmaceutical pipelines with clear value certainty, while remaining cautious toward pure technology platforms. Deep Intelligent Pharma\u2019s breakthroughs in its <\/span>underlying technical architecture<\/b> may explain why it has gained strong and continuous investor recognition.<\/span><\/p>\n

First, from a pharmaceutical development workflow perspective, Deep Intelligent Pharma does not focus on replacing isolated functions. Instead, it proposes the concept of <\/span>\u201csingle-neuron inefficacy\u201d<\/b>, drawing on deep insights from brain science to cultivate AI into <\/span>autonomous digital scientist teams with domain-specific cognition<\/b>.<\/span><\/p>\n

Through a <\/span>decentralized, collaborative, and self-evolving \u201cbionic brain\u201d<\/b>, Deep Intelligent Pharma has built an autonomous AI agent cluster capable of executing the <\/span>entire clinical trial workflow<\/b> with extreme precision.<\/span><\/p>\n

Traditional clinical development involves multiple complex stages such as regulatory submission, trial design, clinical operations, and data management. Deep Intelligent Pharma reconstructs this complexity into a <\/span>\u201cbionic brain\u201d composed of tens of thousands of high-precision atomic agents<\/b>, including:<\/span><\/p>\n